167 related articles for article (PubMed ID: 23886838)
1. Osteo-promoting effects of insulin-like growth factor I (IGF-I) in a mouse model of type 1 diabetes.
Fowlkes JL; Nyman JS; Bunn RC; Jo C; Wahl EC; Liu L; Cockrell GE; Morris LM; Lumpkin CK; Thrailkill KM
Bone; 2013 Nov; 57(1):36-40. PubMed ID: 23886838
[TBL] [Abstract][Full Text] [Related]
2. Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model.
Fowlkes JL; Thrailkill KM; Liu L; Wahl EC; Bunn RC; Cockrell GE; Perrien DS; Aronson J; Lumpkin CK
J Bone Miner Res; 2006 Sep; 21(9):1359-66. PubMed ID: 16939394
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor-I (rhIGF-I) therapy in adults with type 1 diabetes mellitus: effects on IGFs, IGF-binding proteins, glucose levels and insulin treatment.
Carroll PV; Umpleby M; Alexander EL; Egel VA; Callison KV; Sönksen PH; Russell-Jones DL
Clin Endocrinol (Oxf); 1998 Dec; 49(6):739-46. PubMed ID: 10209561
[TBL] [Abstract][Full Text] [Related]
4. Impaired osteogenesis of T1DM bone marrow-derived stromal cells and periosteum-derived cells and their differential in-vitro responses to growth factor rescue.
Filion TM; Skelly JD; Huang H; Greiner DL; Ayers DC; Song J
Stem Cell Res Ther; 2017 Mar; 8(1):65. PubMed ID: 28283030
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human insulin-like growth factor-I treatment inhibits gluconeogenesis in a transgenic mouse model of type 2 diabetes mellitus.
Pennisi P; Gavrilova O; Setser-Portas J; Jou W; Santopietro S; Clemmons D; Yakar S; LeRoith D
Endocrinology; 2006 Jun; 147(6):2619-30. PubMed ID: 16513827
[TBL] [Abstract][Full Text] [Related]
6. Dual hormonal replacement therapy with insulin and recombinant human insulin-like growth factor (IGF)-I in insulin-dependent diabetes mellitus: effects on the growth hormone/IGF/IGF-binding protein system.
Thrailkill K; Quattrin T; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Kotlovker D; Giltinan D; Gesundheit N; Martha P
J Clin Endocrinol Metab; 1997 Apr; 82(4):1181-7. PubMed ID: 9100593
[TBL] [Abstract][Full Text] [Related]
7. The complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its binding protein-5 (IGFBP-5) induces local bone formation in murine calvariae and in rat cortical bone after local or systemic administration.
Bauss F; Lang K; Dony C; Kling L
Growth Horm IGF Res; 2001 Feb; 11(1):1-9. PubMed ID: 11437468
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus.
Mohamed-Ali V; Pinkney J
Treat Endocrinol; 2002; 1(6):399-410. PubMed ID: 15832492
[TBL] [Abstract][Full Text] [Related]
9. Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. RhIGF-I in IDDM Study Group.
Thrailkill KM; Quattrin T; Baker L; Kuntze JE; Compton PG; Martha PM
Diabetes Care; 1999 Apr; 22(4):585-92. PubMed ID: 10189536
[TBL] [Abstract][Full Text] [Related]
10. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
[TBL] [Abstract][Full Text] [Related]
11. Musculoskeletal effects of the recombinant human IGF-I/IGF binding protein-3 complex in osteoporotic patients with proximal femoral fracture: a double-blind, placebo-controlled pilot study.
Boonen S; Rosen C; Bouillon R; Sommer A; McKay M; Rosen D; Adams S; Broos P; Lenaerts J; Raus J; Vanderschueren D; Geusens P
J Clin Endocrinol Metab; 2002 Apr; 87(4):1593-9. PubMed ID: 11932288
[TBL] [Abstract][Full Text] [Related]
12. Bone formation is impaired in a model of type 1 diabetes.
Thrailkill KM; Liu L; Wahl EC; Bunn RC; Perrien DS; Cockrell GE; Skinner RA; Hogue WR; Carver AA; Fowlkes JL; Aronson J; Lumpkin CK
Diabetes; 2005 Oct; 54(10):2875-81. PubMed ID: 16186388
[TBL] [Abstract][Full Text] [Related]
13. Short-term systemic insulin-like growth factor-1 is unable to prevent cyclosporin A-induced osteopenia in the rat.
Mann GN; Sass DA; Chen HK; Buchinsky FJ; Bryer HP; Ma YF; Jee WS; Rucinski B; Epstein S
Calcif Tissue Int; 1996 Jul; 59(1):38-44. PubMed ID: 8661983
[TBL] [Abstract][Full Text] [Related]
14. The effects of recombinant human insulin-like growth factor (rhIGF)-1 and rhIGF-1/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy.
Narusawa K; Nakamura T; Suzuki K; Matsuoka Y; Lee LJ; Tanaka H; Seino Y
J Bone Miner Res; 1995 Dec; 10(12):1853-64. PubMed ID: 8619365
[TBL] [Abstract][Full Text] [Related]
15. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
[TBL] [Abstract][Full Text] [Related]
16. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes.
Clemmons DR; Sleevi M; Allan G; Sommer A
J Clin Endocrinol Metab; 2007 Jul; 92(7):2652-8. PubMed ID: 17426090
[TBL] [Abstract][Full Text] [Related]
17. Dual hormonal replacement with insulin and recombinant human insulin-like growth factor I in IDDM. Effects on glycemic control, IGF-I levels, and safety profile.
Quattrin T; Thrailkill K; Baker L; Litton J; Dwigun K; Rearson M; Poppenheimer M; Giltinan D; Gesundheit N; Martha P
Diabetes Care; 1997 Mar; 20(3):374-80. PubMed ID: 9051390
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human insulin-like growth factor I (IGF-I): risks and benefits of normalizing blood IGF-I concentrations.
Clark RG
Horm Res; 2004; 62 Suppl 1():93-100. PubMed ID: 15761240
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 (IGF-1) protects NOD mice from insulitis and diabetes.
Bergerot I; Fabien N; Maguer V; Thivolet C
Clin Exp Immunol; 1995 Nov; 102(2):335-40. PubMed ID: 7586687
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent effects of recombinant human insulin-like growth factor (IGF)-I/IGF binding protein-3 complex on overnight growth hormone secretion and insulin sensitivity in type 1 diabetes.
Saukkonen T; Amin R; Williams RM; Fox C; Yuen KC; White MA; Umpleby AM; Acerini CL; Dunger DB
J Clin Endocrinol Metab; 2004 Sep; 89(9):4634-41. PubMed ID: 15356074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
